Literature DB >> 19168109

Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine.

Jun Zhang1, Chong-Bo Liu, Rong-Cheng Li, Yi-Min Li, Ying-Jie Zheng, Yan-Ping Li, Dong Luo, Bai-Bin Pan, Yi Nong, Sheng-Xiang Ge, Jun-Hui Xiong, James Wai-Kuo Shih, Mun-Hon Ng, Ning-Shao Xia.   

Abstract

The candidate recombinant hepatitis E vaccine, HEV 239, protect monkeys against infection by hepatitis E virus (HEV). The safety and immunogenicity of the vaccine for humans was assessed in a randomized controlled phase II clinical trial. The study was conducted in an endemic area of southern China and consisted of a dose scheduling, involving 457 adults and a dose escalation component involving 155 high school students. The results showed that the vaccine is safe and immunogenic for humans and suggest that it could prevent new HEV infection.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19168109     DOI： 10.1016/j.vaccine.2008.12.061

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  35 in total

1.  Hepatitis: Hepatitis E vaccination--is HEV 239 the breakthrough?

Authors:  Heiner Wedemeyer; Sven Pischke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-01       Impact factor: 46.802

Review 2.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Hepatitis E: are psychiatric patients on special risk?

Authors:  Claudia Reinheimer; Regina Allwinn; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2011-10-18       Impact factor: 3.402

4.  Characterization of hepatitis E virus recombinant ORF2 proteins expressed by vaccinia viruses.

Authors:  Nereida Jiménez de Oya; Estela Escribano-Romero; Ana-Belén Blázquez; María Lorenzo; Miguel A Martín-Acebes; Rafael Blasco; Juan-Carlos Saiz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

5.  Novel risk factors associated with hepatitis E virus infection in a large outbreak in northern Uganda: results from a case-control study and environmental analysis.

Authors:  Christopher M Howard; Thomas Handzel; Vincent R Hill; Scott P Grytdal; Curtis Blanton; Saleem Kamili; Jan Drobeniuc; Dale Hu; Eyasu Teshale
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

Review 6.  Development of new hepatitis E vaccines.

Authors:  Yufeng Cao; Zhenhong Bing; Shiyu Guan; Zecai Zhang; Xinping Wang
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

7.  Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.

Authors:  Xiaoqing Cheng; Yueyuan Zhao; Xuefeng Zhang; Hui Jin; Jie Min
Journal:  Hum Vaccin Immunother       Date:  2017-04-27       Impact factor: 3.452

8.  Effect of freezing on recombinant hepatitis E vaccine.

Authors:  Kelei Li; Fangyu Dong; Fan Gao; Lianlian Bian; Shiyang Sun; Ruixiao Du; Yalin Hu; Qunying Mao; Haifa Zheng; Xing Wu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

9.  Estimating the burden of maternal and neonatal deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection.

Authors:  Emily S Gurley; Amal K Halder; Peter K Streatfield; Hossain M S Sazzad; Tarique M Nurul Huda; M Jahangir Hossain; Stephen P Luby
Journal:  Am J Public Health       Date:  2012-10-18       Impact factor: 9.308

Review 10.  Hepatitis E virus: Current epidemiology and vaccine.

Authors:  Xing Wu; Pan Chen; Huijuan Lin; Xiaotian Hao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.